Press Releases June 22, 2026 08:45 AM

Enlivex Treasury Portfolio Update: RAIN Holdings Valued at Approximately $1.14 Billion

Enlivex announces $1.14 billion valuation of RAIN token holdings, boosting treasury value and spotlighting dual strategy of longevity therapeutics and blockchain assets.

By Jordan Park
Share
Twitter Reddit Facebook LinkedIn
ENLV

Enlivex Ltd. updates its treasury portfolio, reporting holdings of approximately 79.6 billion RAIN tokens valued at about $1.14 billion as of June 20, 2026. This substantial asset contributes to a Treasury NAV per Share of $4.671, reflecting strong market valuation of its blockchain-based prediction markets treasury strategy alongside its clinical-stage immunotherapy programs targeting age-related conditions.

Enlivex Treasury Portfolio Update: RAIN Holdings Valued at Approximately $1.14 Billion
ENLV
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Enlivex holds over 79.5 billion RAIN tokens valued at approximately $1.14 billion, enhancing its treasury assets significantly.
  • The treasury NAV per share stands at $4.671, showcasing robust market confidence in the company's strategy combining longevity therapeutics with digital asset exposure.
  • Enlivex advances its Allocetra™ clinical-stage immunotherapy focused on inflammatory and age-related diseases, while capitalizing on the emerging decentralized prediction markets ecosystem via the Rain protocol on Arbitrum.
  •   As of June 18, 2026, Enlivex held 79,568,550,005 RAIN tokens with a total value of approximately $1.14 billion1.

Nes-Ziona, Israel, June 22, 2026 (GLOBE NEWSWIRE) -- Enlivex Ltd. (Nasdaq: ENLV, "Enlivex" or the "Company"), a quality longevity company powered by a prediction markets treasury, today provided an update on its RAIN token holdings. As of June 20, 2026, the Company held 79,568,550,005 RAIN tokens with a total value of approximately $1.14 billion1.

The Company's treasury metrics, as reflected on its public market data dashboard, indicate a Treasury NAV per Share of $4.671 as of June 20, 2026, based on current RAIN token holdings relative to total number of the Company’s ordinary shares outstanding. The updated unaudited mark-to-market treasury metrics are publicly available on the Company's website at https://enlivex.com/dashboard/. Detailed information about the token’s listing on various exchanges, daily trading volume and other parameters can be found on https://coinmarketcap.com/currencies/rain/.  

About Enlivex

Enlivex is a quality longevity company powered by a prediction markets treasury. The Company is advancing Allocetra™, an advanced clinical-stage immunotherapy targeting inflammatory conditions associated with aging, with a primary focus on age-related osteoarthritis. In addition to its clinical programs, Enlivex operates a prediction markets treasury strategy built around the Rain protocol, the leading decentralized prediction markets infrastructure on Arbitrum. This dual strategy combines the development of quality longevity therapeutics with exposure to the emerging prediction markets ecosystem.

Forward-looking statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements may be identified by words such as "expects," "plans," "projects," "will," "may," "anticipates," "believes," "should," "would," "could," "intends," "estimates," "suggests," "target," "has the potential to," "goal," and other words of similar meaning, including statements relating to the anticipated benefits of the Company's digital asset treasury strategy; the assets to be held by the Company; the expected future market, price, trading activity, and liquidity of the RAIN token; the impact of expanded exchange listings and increased token liquidity on market participation and accessibility; the potential effects of digital asset liquidity on the liquidity of the Company's ordinary shares; macroeconomic, political, and regulatory conditions surrounding digital assets; the Company's plans for value creation and strategic positioning; market size and growth opportunities; regulatory conditions; competitive position; technological and market trends; future financial condition and performance; expected clinical trial results; market opportunities for the results of current clinical studies and preclinical experiments; and the effectiveness of, and market opportunities for, ALLOCETRA™ programs.

Each forward-looking statement contained in this press release is subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statement. Applicable risks and uncertainties include, among others, the risk of failure to realize the anticipated benefits of the Company's digital asset treasury strategy; changes in business, market, financial, political, and regulatory conditions; risks relating to the Company's operations and business, including the highly volatile nature of the price, trading volume, and liquidity of RAIN and other cryptocurrencies; risks associated with digital asset exchange listings, trading venues, and market infrastructure; the risk that the price and liquidity of the Company's ordinary shares may be correlated with the price or liquidity of the digital assets it holds; risks related to increased competition in the industries in which the Company operates; risks relating to significant legal, commercial, regulatory, and technical uncertainty regarding digital assets generally; risks relating to the treatment of crypto assets for U.S. and foreign tax purposes; and those risks and uncertainties identified in the Company's filings with the Securities and Exchange Commission. The forward-looking statements in this press release speak only as of the date of this document, and the Company undertakes no obligation to update or revise any of these statements, except as required by applicable law.

Enlivex contact

Shachar Shlosberger
CFO
Enlivex Ltd.
[email protected]



1 Valuation calculated using the closing price of the token as quoted on https://coinmarketcap.com/currencies/rain/


Risks

  • Volatility and liquidity risks associated with the RAIN token and other cryptocurrencies may impact the company’s financial stability and share price.
  • Regulatory uncertainties and evolving legal conditions surrounding digital assets pose potential challenges to Enlivex’s treasury strategy and operations.
  • Market and business risks including competition, clinical trial success, and broader macroeconomic or political conditions could affect future performance and asset valuations.

More from Press Releases

Cosmos Health Builds Contract Manufacturing Orderbook to Over 25 Million Units; Division Positioned to Generate Over $10 Million in Recurring Annual Profit Jun 22, 2026 Dogfish Head & Rolling Stone Celebrate 250 Years of American Music with Exclusive Whiskey Collaboration Jun 22, 2026 Teamshares to participate in Northland Growth Conference on June 23, 2026 Jun 22, 2026 BrewDog Bars Draw Record Fan Turnout as Global Tournament Fever Drives Double-Digit Growth Jun 22, 2026 Paychex Named One of America's Most Trustworthy Companies by Newsweek Jun 22, 2026